SAN DIEGO--(BUSINESS WIRE)--May 8, 2006--Imagenetix (OTCBB:IAGX - News) today announced the successful completion of in vitro studies demonstrating the significant inhibitory function of its novel pharma compound, 1-tetradecanol complex (1-TDC). The main findings include:
